A comparative study of the efficacy and safety of Hemoforce Family in the treatment of iron deficiency anaemia in a tertiary healthcare facility in Northern Ghana.

Shalina Healthcare0 个研究点目标入组 200 人开始时间: 2022年9月21日最近更新: 2023年5月29日

适应症

试验速览

暂无简介。

•Male or female (=12 years) suffering from iron deficiency anaemia having hemoglobin between 9 to 12 g/dl.
•Patients or parents willing to provide written informed consent to use personal and/or health data prior to the entry into the study.

•Anaemia not linked to iron deficiency.
•Hemoglobin less than 9 g/dL.
•Allergy to iron derivatives.
•Any medical disorder like diabetes or tuberculosis (TB), viral hepatitis cirrhosis, renal disease, autoimmune disease.
•Those who had received parenteral iron treatment earlier within 3 months before the start of the study.
•Patients with history of chronic blood loss.
•Alcohol abuse within past 6 months.
•Hemosiderosis, hemochromatosis or other iron storage disorders.
•Patients with a history or present illness that is a malignant tumor or autoimmune disease.
•Patients who underwent oral administration of an iron preparation (including an over-the-counter drug or supplement) within 4 weeks before the screening.

发起方

Shalina Healthcare